Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.00
-0.80 (-3.10%)
At close: May 15, 2026, 4:00 PM EDT
25.10
+0.10 (0.40%)
After-hours: May 15, 2026, 7:35 PM EDT

Ultragenyx Pharmaceutical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
669.71673560434363.33351.41
Revenue Growth (YoY)
13.48%20.18%29.03%19.45%3.39%29.66%
Cost of Revenue
110.34109774528.3216.01
Gross Profit
559.37564483389335.01335.4
Selling, General & Admin
349.2349321310278.14219.98
Research & Development
771.23750698648705.79497.15
Total Operating Expenses
1,1201,0991,019958983.93717.14
Operating Income
-561.06-535-536-569-648.92-381.74
Interest Income
24.1725372711.071.93
Interest Expense
-68.66-62-63-66-43.02-29.42
Other Non-Operating Income (Expense)
1.771-5-1-20.87-43.75
Total Non-Operating Income (Expense)
-42.72-36-31-40-52.81-71.24
Pretax Income
-605.23-571-567-609-701.73-452.98
Provision for Income Taxes
3.6942-25.71.04
Net Income
-608.92-575-569-607-707.42-454.03
Net Income to Common
-608.92-575-569-607-707.42-454.03
Shares Outstanding (Basic)
1009991747068
Shares Outstanding (Diluted)
1009991747068
Shares Change (YoY)
6.59%8.95%23.13%5.13%3.13%11.42%
EPS (Basic)
-6.11-5.83-6.29-8.25-10.12-6.70
EPS (Diluted)
-6.11-5.83-6.29-8.25-10.12-6.70
Shares Outstanding
98.396.692.582.3270.269.35
Free Cash Flow
-502.2-472-421-519-496.59-411.79
Free Cash Flow Per Share
-5.04-4.79-4.65-7.06-7.10-6.07
Gross Margin
83.52%83.80%86.25%89.63%92.21%95.44%
Operating Margin
-83.78%-79.49%-95.71%-131.11%-178.60%-108.63%
Profit Margin
-90.92%-85.44%-101.61%-139.86%-194.70%-129.20%
FCF Margin
-74.99%-70.13%-75.18%-119.59%-136.68%-117.18%
EBITDA
-527.05-500-500-543-630.7-368.5
EBITDA Margin
-78.70%-74.29%-89.29%-125.11%-173.59%-104.86%
EBIT
-561.06-535-536-569-648.92-381.74
EBIT Margin
-83.78%-79.49%-95.71%-131.11%-178.60%-108.63%
Effective Tax Rate
-0.61%-0.70%-0.35%0.33%-0.81%-0.23%
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q